🔴 Novartis is trading 12.51% down today after del-desiran failed to show significant improvement

Novartis is trading 12.51% down at $139.97 after del-desiran failed to achieve statistically significant improvement in the Phase III HARBOR trial for myotonic dystrophy.

• Reuters reported this was the company’s second major clinical setback within days, following pelacarsen’s cardiovascular-trial failure.
• The setbacks are intensifying concerns about Novartis’s growth pipeline.
• The broader market is only modestly weaker, making the company-specific drug failures the primary catalyst.